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Respiratory Syncytial Virus Infection in Cattle
Abstract
Bovine respiratory syncytial virus (RSV) is a cause of respiratory disease in cattle worldwide. It has an integral
role in enzootic pneumonia in young dairy calves and summer pneumonia in nursing beef calves.
Furthermore, bovine RSV infection can predispose calves to secondary bacterial infection by organisms such
asMannheimia haemolytica, Pasteurella multocida, and Histophilus somni, resulting in bovine respiratory disease
complex, the most prevalent cause of morbidity and mortality among feedlot cattle. Even in cases where
animals do not succumb to bovine respiratory disease complex, there can be long-term losses in production
performance. This includes reductions in feed efficiency and rate of gain in the feedlot, as well as reproductive
performance, milk production, and longevity in the breeding herd. As a result, economic costs to the cattle
industry from bovine respiratory disease have been estimated to approach $1 billion annually due to death
losses, reduced performance, and costs of vaccinations and treatment modalities. Human and bovine RSV are
closely related viruses with similarities in histopathologic lesions and mechanisms of immune modulation
induced following infection. Therefore, where appropriate, we provide comparisons between RSV infections
in humans and cattle. This review article discusses key aspects of RSV infection of cattle, including
epidemiology and strain variability, clinical signs and diagnosis, experimental infection, gross and microscopic
lesions, innate and adaptive immune responses, and vaccination strategies.
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Abstract
Bovine respiratory syncytial virus (RSV) is a cause of respiratory disease in cattle worldwide. It has an integral role in enzootic
pneumonia in young dairy calves and summer pneumonia in nursing beef calves. Furthermore, bovine RSV infection can predispose
calves to secondary bacterial infection by organisms such as Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni,
resulting inbovine respiratorydisease complex, themost prevalent causeofmorbidity andmortality among feedlot cattle. Even in cases
where animals do not succumb to bovine respiratory disease complex, there can be long-term losses in production performance. This
includes reductions in feed efficiency and rateof gain in the feedlot, aswell as reproductive performance,milk production, and longevity
in the breeding herd. As a result, economic costs to the cattle industry from bovine respiratory disease have been estimated to
approach $1 billion annually due to death losses, reduced performance, and costs of vaccinations and treatment modalities. Human
and bovine RSV are closely related viruses with similarities in histopathologic lesions and mechanisms of immune modulation induced
following infection. Therefore, where appropriate, we provide comparisons between RSV infections in humans and cattle. This review
article discusses key aspects of RSV infection of cattle, including epidemiology and strain variability, clinical signs and diagnosis, experi-
mental infection, gross and microscopic lesions, innate and adaptive immune responses, and vaccination strategies.
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Bovine Respiratory Syncytial Virus
Epidemiology and Strain Variability
Epidemiology
The first study to propose an involvement of respiratory syncy-
tial virus (RSV) in respiratory disease in cattle was published
several years after the original isolation and characterization
of human RSV (hRSV). In 1968, Doggett et al16 determined
that bovine sera contained neutralizing antibody against hRSV,
which suggested that a similar virus might exist in cattle. Pub-
lished reports from respiratory disease outbreaks in several
European countries39,63,91 in the early 1970s identified viruses
isolated from cattle that were closely related to hRSV. During
this time, Inaba et al38 isolated what appeared to be a new virus
from cases of acute bovine respiratory disease in Japan, ini-
tially referred to as Nomi virus but later identified as bovine
RSV (bRSV).37 Subsequently, bRSV was confirmed in bovine
respiratory disease outbreaks in the United States in published
reports in 197467 and 1975.75
Since these initial reports, bRSV has been detected in cattle
herds worldwide, with rates of infection likely affected by man-
agement practices. In fact, estimates from several countries
suggest that the frequency of bRSV exposure in some dairy and
beef herds exceeds 50%.23 Studies from Sweden have shown
that between 40% to 100% of animals in a herd were seroposi-
tive, depending on geographic location and animal density.61 A
high frequency of bRSV serum antibodies in cattle (>70%) was
reported in a sample of 50 Danish herds.84 There are fewer pub-
lished reports on the prevalence of bRSV in Britain, although
results from a national survey in England and Wales suggest
that most adult cattle have been exposed to bRSV.64 In South
African feedlots experiencing outbreaks of respiratory infec-
tions, the seroprevalence to bRSV was found to be 43%.90 High
frequency of bRSV seroconversion during the first month after
arrival was found among feedlot calves in Canada.54 Similarly,
in the United States, results from a study of feedlot cattle
reported a high rate of seroconversion.12 Furthermore, the
authors found bRSV seropositive rates in range cattle of 28%
in calves, 49% in yearlings, and 70% in mature cows.
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Significant regional differences in the frequency of bRSV have
also been reported from studies in Mexico.70
bRSV-associated disease is most pronounced in calves less
than 6 months of age, and infection can occur even in the pres-
ence of maternal antibodies. It has been estimated in some geo-
graphic areas that more than 70% of calves have been exposed
by the age of 12 months.86 As with hRSV, reinfections in
calves are common. Viruses from recurrent bRSV infections
varied by up to 11% in sequence, even in closed herds.47 The
authors proposed that based on the high degree of diversity,
it is likely that recurrent infections result from reintroduction
of bRSV into the herd before each new outbreak. Transmission
of bRSV may occur via aerosol droplets from, or direct contact
with, infected animals or indirectly via contaminated surfaces.34
Seasonal periodicity is seen with bRSV, with most common
occurrences of infections in the fall and winter months in tempe-
rate environments.89
In addition to temperature fluctuations, additional stress fac-
tors that can increase the risk of bRSV infection include but are
not limited to weaning, handling, transportation, mixing of cat-
tle from different sources, crowding, and dusty environments.
Clinical signs are frequently seen 7 to 10 days following a
stressful event (eg, transport to a feedlot) but may be seen as
late as 30 days or more after arrival. Respiratory viruses are
well recognized as primary pathogens, where even uncompli-
cated infections cause substantial production losses. However,
importantly, these viruses may predispose the calf to secondary
bacterial infections, such asMannheimia haemolyica, Pasteur-
ella multocida, Histophilus somni, or Mycoplasma bovis,
resulting in the bovine respiratory disease complex, the leading
cause of morbidity and mortality in US feedlots. Its economic
impact is considerable due to death losses, reduced perfor-
mance, and costs of vaccination and treatment.
Strain Variability
bRSV belongs to the family Paramyxoviridae, subfamily
Pneumovirinae, and genus Pneumovirus. Pneumoviruses are
single-stranded, negative-sense RNA viruses with a genome
of approximately 15.2 kb. The RSV viral RNA is transcribed
into 10 major subgenomic mRNAs encoding 11 proteins,
because the M2 gene encodes 2 proteins. Associated with the
genomic RNA are nucleocapsid (N), phosphoprotein, large
polymerase, and associated proteins, as well as transcriptional
antitermination factor M2-1 and RNA regulatory protein
M2-2. There are 3 transmembrane surface glycoproteins: attach-
ment (G), fusion (F), and small hydrophobic. A nonglycosylated
matrix or membrane protein (M) is associated with the inner face
of the envelope. Finally, there are 2 nonstructural (NS) proteins
that accumulate in infected cells: NS1, NS2.
RSV has been classified into 2 subgroups, A and B, based on
antigenic and genetic differences.1,13 bRSV isolates can be
classified into subgroups based on reactivity of mAb to the G
protein, although these may represent variants of a single major
antigenic group.15,19 The F protein is a type I viral fusion pro-
tein synthesized as a precursor that is proteolytically cleaved by
a furin into disulfide-linked fragments.57 Although bRSV iso-
lates possess antigenically heterogeneous G proteins, a type
II integral membrane protein, the nucleotide sequences have
been shown to be less variable than for hRSV.19,87 The F and
G glycoproteins contain the main neutralization and protective
epitopes. For RSV, the attachment protein is a major target of
the host anti-RSV antibody response,22 and certain regions may
be under immune selection.95 However, immunologic pres-
sures may differ between bRSV and hRSV, as suggested by dif-
ferences in the variability of the central hydrophobic region of
the G protein of these viruses.65
bRSV Diagnosis, Experimental Infection, and Pathology
Clinical Signs and Diagnosis of Field Cases. The incubation time for
bRSV is estimated to be 2 to 5 days. Infection can be subclini-
cal and involve the upper respiratory tract or both the upper and
lower regions of the respiratory tree.87 Clinical signs of bRSV
infections can range from minimal to severe with dyspnea and
death. Affected calves can have tachypnea, ocular serous secre-
tions, dry muzzle, reduced activity, anorexia, and fevers up to
40C. With severe infections, dyspnea can be pronounced and
marked. These signs coincide with bRSV infection, during
which viral replication is detectable beginning at 2 to 3 days
postinfection and continues until 7 to 10 days postinfection.
There has been a biphasic pattern of clinical signs noted follow-
ing some BRSV infections.10 However, the mechanistic basis
underlying this phenomenon is not fully understood. In
grouped calves, individual animals can become infected, but
there can be spread involving multiple calves. With subclinical
infections, animals may have some loss of feed intake and,
thereby, a subtle reduction in weight gain and activity. With
severe infections, however, anorexia and reduced water con-
sumption can result in weight loss and dehydration in just a few
days. Those animals that do survive severe infection lag to
varying degrees in weight gain and growth. They are also sus-
ceptible to secondary bacterial infections with pathogens such
as M. haemolytica, P. multocida, H. somni, and M. bovis that
further alter growth.
Immunofluorescence stains have been used to identify
bRSV antigens in frozen lung samples; however, cellular and
structural resolution is difficult with fluorescent images, and
tissues can have endogenous (background) fluorescence. In
many laboratories, the virus is detected with immunohisto-
chemistry (IHC) of lung tissue fixed in formalin and processed
(Fig. 1). IHC sections allow excellent assessment of cellular
structures and lesions compared to immunofluorescence,
although in practical terms, many samples submitted to diag-
nostic laboratories have some degree of autolysis due to the
time that it takes for samples to be collected from cattle in the
field or in feedlots and for immersion into formalin. Autolysis
can affect fluorescence and IHC staining and assessment of his-
topathologic lesions.
Additional diagnostic tests include polymerase chain reac-
tion (PCR), to identify the simple presence of viral genome,
or real-time reverse transcription PCR (RT-PCR), to determine
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the relative level of bRSV mRNA of either F protein or nucleo-
protein. A commercial kit detects all bRSV strains assessed
with 99.3% efficiency and a detection limit of 0.1 TCID50
(50% tissue culture infective dose).83 This kit had much higher
sensitivity than that of fluorescent antibody assays. A 1-step
multiplex real-time RT-PCR assay for bRSV, bovine herpes-
virus 1, and bovine parainfluenza virus 3 was also found to
be more sensitive than immunofluorescence (and virus isola-
tion).81 Intranasal vaccination (Rispoval RS with PI3 IntraNa-
sal, Pfizer) can result in bRSV detection by an RT-PCR kit
(Taqvet BRSV, Laboratoire Service International) for beyond
14 days in some calves.82
Viral isolation and titers can be determined from lung sam-
ples as well. Unfortunately, bRSV is somewhat labile and can
be difficult to isolate and titrate from tissue samples. This is
especially true for samples from the field or tissues that are
packaged and shipped to diagnostic laboratories. A 1-step
enzyme-linked immunosorbent assay has been developed
recently and appears to have advantages in terms of sensitivity
in comparison to an antigen-capture enzyme immunoassay. A
strip test designed for detection of human strains of RSV can
detect bRSV in experimentally infected calves.76
At the diagnostic and pathology laboratories at Iowa State
University, bRSV cases are routinely assessed by postmortem
examination, histopathology, IHC, RT-PCR, and, less fre-
quently, viral isolation. In 2012, the diagnostic laboratory had
45 bovine respiratory disease cases diagnosed with bRSV.
Cases originated from not only Iowa but also Nebraska,
Illinois, Minnesota, Ohio, and Virginia, and the average age
of affected calves was 6 to 7 months. Peak numbers of cases
were seen in the fall, primarily in November and December.
Concurrent infections with infectious bovine rhinotracheitis,
Figure 1. Lung; calf of indeterminate age. Immunohistochemical detection of respiratory syncytial virus (RSV) antigen in the lung of a calf in which a
bronchiole is somewhat dilated and variably filledwith cell debris,macrophages, andoccasional neutrophils. There are areas of ulceration and erosion,
and remaining epithelial cells have viral antigen within the cytoplasm. Around this airway, the lung is consolidated and contains moderate infiltrates of
lymphocytes,macrophages, andoccasional neutrophils.Figure2.Lung; 3-month-old calf; 7 days after experimental infectionwithbovineRSV (bRSV).
Notemultifocal to coalescing areas of plum-red consolidation cranial and ventral aspects of right cranial andmiddle lobes, and cranial aspect of caudal
lobesConsolidated areas surround anddivide foci of pale pinkhyperinflated lung.Figure3.Lung; 3-month-old calf; 7 days after experimental infection
with bRSV.Alveolar septae are thickeneddue to cellular infiltrates ofmacrophages, lymphocytes, and lesser numbers of neutrophils.Hematoxylin and
eosin. Figure 4. Lung; 3-month-old calf; 7 days after experimental infection with bRSV. Bronchioles are filled with neutrophils, sloughed epithelial
cells, and necrotic cell debris. Hematoxylin and eosin.Figure5. Lung; 3-month-old calf; 14 days after experimental infectionwith bRSV. Bronchiolitis
obliterans is characterized by bronchiolar lumens partially occluded by a polypoid fibrocellular mass composed of mononuclear inflammatory cells,
epithelial cells, fibrin, and multinucleated syncytial cells, all supported by a fine fibrovascular stroma. Inset: Fibrocellular mass protrudes into bronch-
iolar lumen partially lined with epithelial cells. Hematoxylin and eosin.
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bovine viral diarrhea virus, P. multocida, M. haemolytica,
M. bovis, H. somni, Arcanobacterium pyogenes and Biberstei-
nia trehalosi were diagnosed in many of these cases. Although
bacterial pathogens were not always isolated, the majority of
cases had microscopic evidence of concurrent bacterial bronch-
opneumonia. The routine postmortem tissue work up in the
diagnostic laboratory includes gross and histopathologic eva-
luations, routine bacterial culture of lung, IHC staining of lung
sections, and a multiplex RT-PCR assay which detects multiple
bovine viral respiratory pathogens and was developed at Iowa
State University.35 In the early stages of clinical disease, tissue
from lesions typical of bRSV in the cranioventral lung fields is
frequently the best sample to use for virus detection.10,48
Experimental Infection. Clinical signs of respiratory disease
observed following experimental infection of calves with bRSV,
while similar to those seen in field cases, have been of varying
degrees of severity. Plausible reasons for the variable results
between studies include differing routes of inoculation, dose of
inoculum, number of times that inoculum was administered, age
of calves, or complicating factors such as secondary bacterial
infection. In comparing a sample of experimental infection stud-
ies, routes of inoculation have included intratracheal, intranasal,
aerosol, or a combination of challenge routes, given once or mul-
tiple times on consecutive days.30,49,69,94,96 In addition, doses of
inocula utilized in these studies have ranged from 102 to 105
tissue culture infective doses and, in others, up to 105 plaque-
forming units. Experimentally infected calves have been shown
to have an elevated temperature beginning at day 2 that persists
until approximately day 7 postinfection. Additionally, increased
respiration rates, nasal discharge, and coughing have been
observed for several days following infection.
Gross and Microscopic Lesions. Lesions observed in field cases or
following experimental infection with bRSV are of a similar
nature. In the lungs of affected animals, gross lesions of bRSV
infection have a cranioventral distribution and are character-
ized by atelectatic, collapsed, deep red-purple lesions that are
rubbery upon palpation. Consolidated lesions can be present
throughout the cranial, middle, and accessory lobes or lobular
in distribution with areas of consolidation distributed multifo-
cally and surrounded by lobules of pink, overinflated lung
(Fig. 2).68 The nasal meatus, trachea, bronchi, and bronchioles
can contain foamy to mucopurulent discharge. In contrast,
caudodorsal lobes are often distended with interlobular,
lobular, or subpleural emphysematous and edematous lesions.
Caudodorsal lung regions may fail to collapse and, due to
emphysema, may be pale. The demarcation between cranio-
ventral consolidation and caudodorsal edematous and emphy-
sematous changes can be well delineated. Variations in gross
lesions may occur with a generalized red discoloration to all
lung lobes and rubbery texture in both cranioventral and caudo-
dorsal regions. Animals that exhibit severe respiratory distress
may present with emphysematous lesions in interlobular or
subpleural locations, resulting in pneumothorax, pneumome-
diastinum, or pneumopericardium.8,44 In some cases,
subcutaneous emphysematous bullae may develop along the
shoulders, back, neck, or perineum.8,44 Pulmonary lymph
nodes (ie, mediastinal and tracheobronchial) may be enlarged,
edematous, or even hemorrhagic.
In cranioventral lobes, microscopic lesions are those of a
bronchointerstitial pneumonia, necrotizing bronchiolitis, syn-
cytia formation, type II pneumocyte hyperplasia, and exudative
or proliferative alveolitis (Figs. 3, 4).10 Alveolar lumens often
contain seroproteinaceous fluid, fibrin casts, cell debris, few
alveolar macrophages, and occasional neutrophils. Nearby
alveoli can contain air and be modestly dilated due to hyperin-
flation. The most consistent feature, necrotizing bronchiolitis,
is characterized by degenerative or necrotic ciliated and nonci-
liated bronchiolar epithelium. Epithelial cell necrosis leads to
ulcerated foci covered by necrotic cell debris with nearby
degenerate cells exhibiting rounded cell borders. Erosion and
ulceration of the epithelial layer may also lead to attenuation
of epithelial cells as they extend over exposed basement mem-
brane. This results in bronchioles lined by flattened cells that
sometimes have a squamous morphology. IHC may reveal viral
antigen in bronchiolar epithelial cells.23 Multinucleated syncy-
tial cells can often be found projecting from the bronchiolar
wall or free in the lumen. Syncytial cells may also be found
in alveoli. Uncommonly, eosinophilic intracytoplasmic viral
inclusions may be seen in syncytial cells as well as mononuc-
lear cells or epithelia. Neutrophilic exudates may be present
within bronchi, bronchioles, or alveoli. Lobular to diffuse inter-
stitial thickening of alveolar septae is seen and is the result of
alveolar capillary congestion, infiltration of inflammatory cells
(ie, lymphocytes, macrophages), and type II pneumocyte
hyperplasia. Interlobular septae are often widened or expanded
by edema and dilation of lymphatic vessels. Lesion severity
does not often correlate with viral load or viral distribution,
suggesting that much of the tissue damage is the result of host
response rather than primary viral infection.23 Tracheobron-
chial lymph nodes of affected cattle are often characterized
by enlarged cortical areas with prominent follicles and
expanded parafollicular areas and medullary cords due to lym-
phocytic hyperplasia. Medullary sinuses often contain macro-
phages, with variable numbers of lymphocytes, plasma cells,
and hemosiderin-laden macrophages and occasional neutro-
phils and eosinophils. With secondary bacterial infections or
bovine respiratory disease complex, tracheobronchial lymph
nodes can have a variety of additional histologic features, rang-
ing from suppurative to lymphocytic and granulomatous.
As the infection progresses, an attempt to repair necrotic air-
ways may result in epithelial hyperplasia and bronchiolitis
obliterans, also known as bronchiolitis fibrosa obliterans, oblit-
erative bronchiolitis, or organizing bronchiolitis (Fig. 5).10
Bronchiolitis obliterans can result after damage to the bronch-
iolar epithelium and has been characterized as ‘‘wound healing
gone awry.’’10 Persistent inflammation with fibrinous exudates
results in attempts to heal through fibroblast infiltration and
neovascularization.10 In as little as 10 days after infection, the
result may be fibrous polyps, covered by respiratory epithe-
lium, extending into the airway lumen, and resulting in
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permanent decreases in airflow and alveolar ventilation.
Bronchiolitis obliterans can be induced by various agents (eg,
viral, bacterial, parasitic, toxic) and is not specific for bRSV.
Ultrastructurally, changes in ciliated and nonciliated epithelial
cells, as well as type I and type II pneumocytes, can range from
acute cell swelling to necrosis.44 Intercellular areas can be
expanded, and epithelial cells may lose intercellular junctions.
Immune Responses to RSV
Innate Immunity. The initiation of an innate immune response is
dependent on the recognition and binding of evolutionarily con-
served pathogen-associated molecular patterns (PAMPs) to pat-
tern recognition receptors (PRRs). Recognition of viral PAMPs
involves at least 3 distinct classes of PRRs: toll-like receptors
(TLRs), retinoic acid–inducible gene I–like receptors, and
nucleotide-binding oligomerization domain–like receptors. Rec-
ognition of RSV infection involves several TLRs, including
TLR2, 3, 4, 7, and 8.4,98 TLR3, which recognizes double-
stranded RNA, and TLR7, which recognizes single-stranded
RNA, are endosomal receptors that are key for the innate recog-
nition of RNA viruses. It has been shown that RSV stimulates
airway epithelial cells via signaling through TLR3 and retinoic
acid–inducible gene I–like receptors, which have been linked
to distinct pathways controlling NF-kB activation.50 The F pro-
tein of bRSV has been reported to bind to TLR4 and, in concert
with MD2 and CD14, also mediate NF-kB activation.51
Recognition of viral infection through PRRs results in pro-
duction of type I IFN and induction of IFN-stimulated genes,
including MxA protein, protein kinase R, ISG15, and 20-50 oli-
goadenylate synthetase. Paramyxoviruses are known to utilize
different mechanisms to affect IFN signaling. hRSV and bRSV
have evolved strategies to inhibit the IFN-induced cellular
response that are dependent on NS proteins. As is characteristic
of pneumoviruses, these viruses have 2 genes that encode for
NS proteins. It has been shown that NS1 and NS2 proteins
cooperatively mediate resistance of bRSV and hRSV to IFN-
stimulated responses in a species-specific manner.6,71 In fact,
the precise mechanism whereby type I IFN responses are
altered varies between these viruses. In the case of bRSV,
NS proteins block phosphorylation and activation of IRF3.7
By comparison, hRSV NS1 and NS2 modulation of type I IFN
responsiveness involves inhibition of Stat2 expression.52
In addition to induction of the IFN response, ligation of
PRRs by viral PAMPs stimulates the early release of inflam-
matory chemokines and cytokines that are important in the
initiation of adaptive immunity. In particular, activation of
antigen-presenting cells such as dendritic cells and macro-
phages is critical for this function. Stimulation of bovine den-
dritic cells with bRSV in vitro results in increased expression
of transcripts for the chemokines RANTES, MIP-1a, MIP2a,
MIP3a, and MCP-2 and the cytokine receptor CCR3.92 Our
laboratory has demonstrated that bRSV infection also induces
inflammatory cytokine production by alveolar macrophages.
Interestingly, the kinetics of induction following bRSV sti-
mulation differs between cytokines. For example, we found
peak induction of IL-1b and IL-12p40 mRNA in alveolar
macrophages occurs on day 3 postinfection in the neonatal
ruminant RSV model, whereas IL-6 mRNA was higher at day
5 than day 3 of infection.18
In addition to antigen-presenting cells, another cell type
thought to be important in bridging the innate and adaptive
immune response is the gd T cell. Recently, our laboratory
demonstrated that stimulation of bovine gd T cells with TLR3
or TLR7 agonists or with in vitro or in vivo bRSV infection
results in robust production of message and protein for the che-
mokines MIP-1a, GM-CSF, and MCP-1.55 Bovine gd T cells
can express the workshop cluster 1 (WC1) receptor and can
be further divided serologically into WC1.1þ andWC1.2þ sub-
sets. Production of proinflammatory mediators following
bRSV stimulation was primarily restricted to WC1.1 and
WC1neg gd T-cell subsets, with the WC1.2þ gd T-cell subset
producing regulatory cytokines, including IL-10 and TGF-b,
suggesting a unique functional difference amongst bovine gd
T-cell populations following bRSV infection.
Recently, our laboratory has shown a significant upregulation
of the innate chemokine IL-8 in areas of lungs with lesions of
RSV-infected calves on day 7 postinfection.69 While the source
of IL-8 in our model is not clear, Gershwin has suggested that
bRSV-infected bovine respiratory/turbinate epithelial cells upre-
gulate transcripts for the proinflammatory cytokines IL-6 and IL-
8.24 Interestingly, our results fit well with data showing that IL-8
is elevated in the respiratory tract of childrenwith RSV bronchio-
litis. Rodents lack a bona fide homologue of IL-8, although mice
have what are considered to be functional homologues, CXCL1
(GRO/KC),CXCL2 (MIP-2), andCXCL5-6 (LIX),whichbelong
to the same major cluster of chemokines. Thus, it is important to
note that the calf can prove useful as an in vivo model for future
exploration into pathways that specifically regulate innate
immune responses during RSV infection.
Adaptive Immune Responses. The development of an adaptive
immune response is required for the control and clearance of
established RSV infections. Following infection, cattle mount
virus-specific antibody and T-cell responses; however, these
responses are weak and transient, as animals can be continuously
reinfected throughout life. It is clear from work in mice and
humans that CD4 and CD8 ab T cells mediate elimination of
a primary RSV infection. T-cell responses are directed at epi-
topes within several RSV proteins, including the N, M, NS2,
M2-1, F, and G.58 The F and G proteins are the major histocom-
patibility antigen class II–restricted targets in humans and cat-
tle,9,58 with the F protein of hRSV being the most thoroughly
studied and described to contain multiple antigenic regions.88
To our knowledge, there are currently no specific bovine leuko-
cyte antigen class II epitopes defined for bRSV in the bovine.
RSV infection in humans induces a mixed Th1- and Th2-type
cytokine response.62 Production of IL-12 by dendritic cells and
early IFNg are required for the priming of an effective
Th1-type cytokine response; however, hRSV has been shown to
interfere with dendritic cell cytokine production and its ability
to initiate the development of a Th1 response.3,9,31 The ensuing
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Th2 polarized response leads to increased disease severity and
lung injury and is thought to block thedevelopment of aneffective
CD8 T-cell response during primary and secondary
challenge.5,9,17,36
Like humans, calves infected with bRSV develop a mixed
cytokine response but favor the development of a Th2-type
immune response following infection. Studies of the cells and
lymph fluid from bRSV-infected calves reveal enhanced IL-4
and IL-13 production in the serum and tissues as early as
day 4 postinfection and increased serum levels of virus-
specific IgE, indicating the establishment of a Th2-type
response.59,77,78 Calves develop IFNg-producing cells and
levels of the cytokine increase in the serum, but neither cell
numbers nor IFNg levels correlate with positive disease out-
come.26 Evidence from humans has suggested that due to the
Th2 nature of the antiviral immune response, hRSV infec-
tion may predispose children to the development of allergies
and asthma later in life.73,74 Interestingly, bRSV infection in
calves has also been shown to predispose to allergic sensi-
tization.25,27 Gershwin et al demonstrated that exposure to
the model allergen ovalbumin during bRSV infection
resulted in significantly increased levels of IL-4, IL-13, and
ovalbumin-specific IgE compared to uninfected control
calves.25
Cytotoxic CD8 T cells play a critical role in the control and
clearance of RSV infection. Bovine CD8 T cells target the M2,
F, N, and G proteins of bRSV.20,79 Calves infected with bRSV
exhibit increased CD8 T-cell infiltration in the lungs, trachea,
and nasopharynx,56 with cytotoxic T-cell activity peaking
between 7 and 10 days postinfection.97 As evidence of their
importance during infection, depletion of CD8 T cells from
bRSV-infected calves results in more severe disease and
increased and sustained viral shedding compared to nonde-
pleted control animals.80 Although bRSV elicits a cytotoxic
T-cell response, it is weak and transient.21,97 Anecdotally, this
is evidenced by the recurring infections that occur commonly
in humans and calves.29,89 Calves infected with bRSV exhibit
limited bRSV-specific cytotoxicity during primary infections
and impaired memory responses following challenge or vacci-
nation.21,97 This may be due to the strong Th2 skewing that
occurs during RSV infection, which acts to inhibit the develop-
ment of an efficient CD8 T-cell response and prevent the estab-
lishment of long-lived memory.9
Humoral immunity plays an important role in defending the
host from RSV infection. While not fully effective, maternal
antibodies may provide some level of protection from severe
bRSV infection;46 however, their presence has also been
described to suppress the development of antibody and T-cell
responses during acute infection.14,45 Calves mount antibody
responses to several bRSV antigens, but the primary targets for
protective humoral responses are the F, G, and NP proteins.79
bRSV-specific IgM and IgA can be detected in the nasal secre-
tions and serum of bRSV-infected calves as early as 8 days
postinfection.45 BRSV-specific IgG2 is not detected in the
serum until 1 to 3 months postinfection, while virus-specific
IgG1 is detectable starting at 13 days postinfection.45 In a
separate study, virus-specific IgE, another antibody associated
with Th2 skewing and airway hyperresponsiveness, was detect-
able in the serum concurrent with the development of clinical
signs.77,78
BRSV Vaccines
There are multiple vaccines currently marketed for bRSV
(killed and modified live) that are generally provided as part
of multivalent products. In the 1960s, a formalin-inactivated
RSV vaccine was developed that not only failed to protect
against hRSV disease but also induced an exaggerated clinical
response to RSV infection in infants who were RSV na¨ive
before vaccination, and 2 infants died.11,41,42 Similar vaccine-
enhanced disease has been reported from 2 cases of natural
bRSV infections in calves.43,72 In the former case, an outbreak
of respiratory tract disease among 5- to 7-month-old calves on a
beef-fattening farm in the Netherlands started 2 days after
administration of a modified-live bRSV vaccine.43 The disease
was severe among vaccinates but absent in nonvaccinated
calves 8 months of age or older. In the latter case, 30% of 8-
month-old Belgian blue calves vaccinated with a b-propiolac-
tone inactivated bRSV vaccine died during a naturally occur-
ring bRSV outbreak. Interestingly, no deaths were recorded
among younger calves not vaccinated.72 Experimentally,
vaccine-enhanced disease has been reproduced in some studies
of calves vaccinated with formalin-inactivated bRSV prepara-
tions2,28 but not in others.60,93 Where bRSV vaccine-enhanced
disease has been observed, there is a bias toward a Th2-like
response, characterized by a reduced CD8 T-cell response and
decreased production of IFNg compared to unvaccinated
bRSV-infected animals.97 Others also observed increases in
serum IgE2,40 and eosinophils in lavage fluid,2 similar to that
observed in children with vaccine-enhanced disease.
Although there is widespread use of bRSV vaccines in
calves, their efficacy is controversial, and given the significant
disease burden associated with bRSV infection, there is a defi-
nite need for improved technologies. BRSV and its target pop-
ulation pose several obstacles with respect to vaccine
development, particularly the need to vaccinate calves with
immature immune systems, induce a response in the face of
maternal antibodies, and effect an appropriate, robust, and
long-lasting immune response.
Researchers are currently studying the use of subunit-based
vaccines and live attenuated bRSV.58 One promising example
reported by Valarcher et al was the success of 2 bRSV strains,
one devoid of NS1 and the other lacking NS2.85 Calves vacci-
nated with either deletion mutant exhibited a robust virus-
specific antibody and CD4 T-cell response and were protected
against virus challenge.85 Interestingly, the NS2 mutant was
more effective than its counterpart. Another group used a sub-
unit approach by immunizing calves with nanoparticles encap-
sulating the N protein of hRSV. In this study, investigators
observed N-specific antibodies and cellular responses, as well
as reduced viral shedding and lung pathology in vaccinated
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calves. Furthermore, the calves did not exhibit vaccine-
enhanced disease.66
An additional area being extensively pursued against bRSV
is the use of newadjuvants coupledwith inactivatedbRSVor sub-
unit vaccines. Among those showing promise is the use of CpG
containing oligodeoxynucleotides53 and immunostimulating
complexes,32,33 both of which induce a robust Th1 skewing.
Immunostimulating complexes are multimers composed of cho-
lesterol, phospholipids, proteins, and Quillaja saponins. Recent
studies byHagglund et al have described the ability bRSV immu-
nostimulating complexes to successfully induce bRSV-specific
cellular and humoral responses and protect from virulent bRSV
challenge in neonatal calves aged 3 to 8 weeks. Interestingly, this
protection was robust despite the presence of significant levels of
maternally derived antibodies.32,33 Further information on novel
approaches to bRSV vaccine development have been recently
reviewed.58
Summary
RSV infection in cattle continues to be a problematic disease
resulting in significant economic losses to the industry due to
decreased productivity coupled with increased costs for treat-
ment. RSV is well recognized as a primary pathogen causing
serious respiratory disease that predisposes cattle to secondary
infection. hRSV and bRSV are closely related viruses with
similarities in histopathologic lesions and mechanisms of
immune modulation induced following infection. The innate
and adaptive responses to RSV in calves are becoming increas-
ingly understood; however, additional mechanistic insight is
needed to better identify prophylactic and therapeutic com-
pounds and vaccine targets.
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